DBV Technologies S.A. (DBVT)
NASDAQ: DBVT
· Real-Time Price · USD
8.70
-0.31 (-3.44%)
At close: May 01, 2025, 3:59 PM
8.85
1.78%
After-hours: May 01, 2025, 07:33 PM EDT
-3.44% (1D)
| Bid | 8.4 |
| Market Cap | 237.69M |
| Revenue (ttm) | 1.16M |
| Net Income (ttm) | -113.65M |
| EPS (ttm) | -5.85 |
| PE Ratio (ttm) | -1.49 |
| Forward PE | -1.08 |
| Analyst | Buy |
| Ask | 9.5 |
| Volume | 34,493 |
| Avg. Volume (20D) | 422,916 |
| Open | 8.83 |
| Previous Close | 9.01 |
| Day's Range | 8.62 - 9.13 |
| 52-Week Range | 0.44 - 9.89 |
| Beta | 0.38 |
About DBVT
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical t...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 22, 2014
Employees 109
Stock Exchange NASDAQ
Ticker Symbol DBVT
Website https://www.dbv-technologies.com
Analyst Forecast
According to 3 analyst ratings, the average rating for DBVT stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 72.51% from the latest price.
Stock Forecasts1 month ago
+58.57%
DBV Technologies shares are trading higher after t...
Unlock content with
Pro Subscription
3 months ago
+10.37%
DBV Technologies shares are trading higher after the company announced 3-year results from its IPITOPE Phase 3 open-label extension study.
